Compare iShares Bitcoin Trust (IBIT) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Johnson & Johnson — how do they compare? iShares Bitcoin Trust trades at $46.7 (market cap $67.31B), while Johnson & Johnson trades at $261.07 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 9.2× iShares Bitcoin Trust's market cap, and Johnson & Johnson pays a 2.09% dividend while iShares Bitcoin Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Johnson & Johnson for 129 Days on average.
| IBIT | JNJ | |
|---|---|---|
Market Cap | $67.31B | $618.09B |
Volume | 56,154,544 | 6,050,983 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $278.43 |
52-Week Low | $33.29 | $186.00 |
Typical Hold Time | 40 Days | 129 Days |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $46.79, down 0.89% with bearish technical signals from oscillators and mixed moving averages. Recent news highlights significant institutional inflows, including a $196 million single-day inflow on October 1, 2026. The stock faces resistance at $47-$48 with support at $44-$46, while RSI levels suggest potential oversold conditions. Financial ratios remain undisclosed in current data.
Outlook hinges on sustained institutional interest amid volatile ETF flows, with Q3 inflows reversing prior outflows. Risks include fee structures impacting returns and market sentiment shifts. Upside potential exists if Bitcoin ETF momentum continues, but investors face exposure to crypto market volatility without direct cash flow benefits.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
